{"id":"investigational-covid-19-vaccine","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Live vaccines","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Interferon-alpha","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Interferon-gamma","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Siponimod","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ocrelizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Rituximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Abatacept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Belimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tocilizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Anakinra","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Leflunomide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Mycophenolate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tacrolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Methotrexate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Etanercept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Adalimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Infliximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Certolizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Golimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Siponimod","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ocrelizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Rituximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Abatacept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Belimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tocilizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Anakinra","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Leflunomide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Mycophenolate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tacrolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Methotrexate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Etanercept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Adalimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Infliximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Certolizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Golimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Siponimod","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ocrelizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Rituximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Abatacept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Belimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tocilizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Anakinra","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Leflunomide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Mycophenolate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tacrolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Methotrexate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Etanercept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Adalimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Infliximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Certolizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Golimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Siponimod","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ocrelizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Rituximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Abatacept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Belimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tocilizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Anakinra","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Leflunomide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Mycophenolate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tacrolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Methotrexate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Etanercept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Adalimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Infliximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Certolizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Golimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Siponimod","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Ocrelizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Rituximab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Abatacept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Belimumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tocilizumab","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Anakinra","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Leflunomide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Mycophenolate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Tacrolimus","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Methotrexate","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Etanercept","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Adalimumab","action":"Avoid","effect":"Decreased vaccine efficacy"}],"commonSideEffects":[{"effect":"Headache","drugRate":"11.7%","placeboRate":"","totalAtRisk":19787,"totalAffected":2310,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"10.1%","placeboRate":"","totalAtRisk":19787,"totalAffected":2008,"trialsReporting":1},{"effect":"Fatigue","drugRate":"9.6%","placeboRate":"","totalAtRisk":19787,"totalAffected":1893,"trialsReporting":1},{"effect":"Myalgia","drugRate":"8.7%","placeboRate":"","totalAtRisk":19787,"totalAffected":1728,"trialsReporting":1},{"effect":"Chills","drugRate":"7.3%","placeboRate":"","totalAtRisk":19787,"totalAffected":1439,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"6.6%","placeboRate":"","totalAtRisk":19787,"totalAffected":1305,"trialsReporting":1},{"effect":"Injection site pain (PAIN)","drugRate":"73.5%","placeboRate":"","totalAtRisk":309,"totalAffected":227,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"58.3%","placeboRate":"","totalAtRisk":309,"totalAffected":180,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"47.6%","placeboRate":"","totalAtRisk":309,"totalAffected":147,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"37.9%","placeboRate":"","totalAtRisk":309,"totalAffected":117,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"36.9%","placeboRate":"","totalAtRisk":309,"totalAffected":114,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"24.9%","placeboRate":"","totalAtRisk":309,"totalAffected":77,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.6%","placeboRate":"","totalAtRisk":309,"totalAffected":45,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"14.2%","placeboRate":"","totalAtRisk":309,"totalAffected":44,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"13.9%","placeboRate":"","totalAtRisk":309,"totalAffected":43,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"12.9%","placeboRate":"","totalAtRisk":309,"totalAffected":40,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"3.9%","placeboRate":"","totalAtRisk":309,"totalAffected":12,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"1.3%","placeboRate":"","totalAtRisk":309,"totalAffected":4,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.3%","placeboRate":"","totalAtRisk":309,"totalAffected":1,"trialsReporting":1}],"contraindications":["History of a severe allergic reaction* (e.g., anaphylaxis†) after a previous dose or to a component of the COVID-19 vaccine‡","History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine"],"specialPopulations":{"Pregnancy":"Pregnant and breastfeeding women were not included in any pre-marketing trial for COVID-19. Pregnant women do not seem to be at higher risk of becoming infected with SARS-CoV-2.","Geriatric use":"text","Paediatric use":"COVID-19 vaccination for children and adolescents is still debated.","Renal impairment":"text","Immunocompromised":"Due to the higher risk of SARS-CoV-2 infection and severe COVID-19, vaccination is currently recommended in these special cohorts.","Hepatic impairment":"text","History of Allergy or Prior SARS-CoV-2 Infection":"Due to the higher risk of SARS-CoV-2 infection and severe COVID-19, vaccination is currently recommended in these special cohorts."}},"trials":[],"aliases":[],"company":"BioNTech","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Investigational COVID-19 Vaccine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:33:29.567092+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:33:50.938025+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:33:35.759096+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Investigational COVID-19 Vaccine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:33:41.746397+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068383/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:33:43.048401+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"BioNTech's investigational COVID-19 vaccine is currently marketed for the prevention of COVID-19 in individuals aged 5 years and older. The vaccine holds a strong market position with key patent protection until 2028, providing a significant barrier to entry for generic competitors. However, the vaccine faces competition from Invivyd’s pemivibart and adintrevimab, which share similar antibody backbones and have demonstrated robust safety and efficacy in clinical trials.","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of the COVID-19 vaccine is not specified, making it challenging for healthcare professionals to understand its effects on the body. Further studies are required to elucidate the technical details of the vaccine's mechanism."},"_companyIR":{"url":"https://www.biontech.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$2.8B","peakSalesEstimate":"$3.819B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=Investigational%20COVID-19%20Vaccine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Investigational COVID-19 Vaccine","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:19.236073+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"pemivibart","company":"Invivyd","advantage":"shares the same antibody backbone as VYD2311"},{"name":"adintrevimab","company":"Invivyd","advantage":"has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19"}],"genericName":"investigational covid-19 vaccine","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT05408312","phase":"PHASE1","title":"Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-06-18","conditions":"COVID-19 Pneumonia","enrollment":234},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT06864143","phase":"PHASE2","title":"A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2","enrollment":1320},{"nctId":"NCT05710783","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2022-11-09","conditions":"SARS-CoV-2 Infection","enrollment":4065},{"nctId":"NCT05303402","phase":"PHASE2, PHASE3","title":"A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-05-12","conditions":"SARS CoV 2 Infection","enrollment":241},{"nctId":"NCT06680375","phase":"PHASE1","title":"A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"COVID-19","enrollment":106},{"nctId":"NCT04839042","phase":"PHASE1","title":"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","status":"COMPLETED","sponsor":"Moat Biotechnology Corporation","startDate":"2021-06-28","conditions":"Covid19","enrollment":196},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT05207137","phase":"NA","title":"Conversation With Family Doctor to Increase COVID-19 Vaccine Uptake","status":"COMPLETED","sponsor":"Norwegian Institute of Public Health","startDate":"2021-12-03","conditions":"COVID-19","enrollment":654},{"nctId":"NCT05972993","phase":"PHASE1","title":"A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-07","conditions":"COVID-19","enrollment":114},{"nctId":"NCT06354998","phase":"PHASE3","title":"A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-04-08","conditions":"SARS-CoV-2","enrollment":217},{"nctId":"NCT06614361","phase":"PHASE2","title":"Community-based Behavioral Intervention to Increase Vaccination Using MOST","status":"WITHDRAWN","sponsor":"New York University","startDate":"2025-04-01","conditions":"COVID 19, Influenza","enrollment":0},{"nctId":"NCT05181709","phase":"PHASE1","title":"A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.","status":"COMPLETED","sponsor":"Sean Liu","startDate":"2022-02-09","conditions":"SARS-CoV-2","enrollment":35},{"nctId":"NCT04854980","phase":"","title":"Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-08-03","conditions":"Covid19, Cancer","enrollment":8},{"nctId":"NCT04904471","phase":"PHASE3","title":"A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2021-06-15","conditions":"COVID-19","enrollment":39663},{"nctId":"NCT05370040","phase":"PHASE1, PHASE2","title":"THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2022-05-05","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05477186","phase":"PHASE1","title":"Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-12","conditions":"COVID-19, SARS-CoV-2","enrollment":185},{"nctId":"NCT04845191","phase":"PHASE1, PHASE2","title":"COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2021-12","conditions":"Covid19","enrollment":0},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT05132907","phase":"PHASE1","title":"Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein","status":"COMPLETED","sponsor":"HDT Bio","startDate":"2022-01-24","conditions":"SARS-CoV2 Infection","enrollment":48},{"nctId":"NCT05743335","phase":"PHASE1","title":"A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-03-07","conditions":"COVID-19, Infectious Disease","enrollment":73},{"nctId":"NCT06191211","phase":"NA","title":"Can Doctors Reduce COVID-19 Misinformation and Increase Vaccine Uptake in Ghana? A Cluster-randomised Controlled Trial","status":"COMPLETED","sponsor":"London School of Economics and Political Science","startDate":"2024-02-07","conditions":"COVID-19","enrollment":7000},{"nctId":"NCT05911048","phase":"PHASE2","title":"A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination","status":"NOT_YET_RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-12-30","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT05911061","phase":"PHASE3","title":"A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination","status":"NOT_YET_RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-12-30","conditions":"COVID-19","enrollment":4950},{"nctId":"NCT05463419","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2022-10-03","conditions":"Covid-19 Vaccine","enrollment":5860},{"nctId":"NCT05576623","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2022-09-14","conditions":"COVID-19, Vaccines","enrollment":320},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":"COVID-19","enrollment":10214},{"nctId":"NCT04773665","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2021-03-15","conditions":"Covid19","enrollment":114},{"nctId":"NCT04652102","phase":"PHASE2, PHASE3","title":"A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-12-11","conditions":"Covid19, SARS-CoV-2","enrollment":39680},{"nctId":"NCT04779138","phase":"NA","title":"Increasing Vaccine Uptake in Underresourced Public Housing Areas","status":"COMPLETED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2021-09-11","conditions":"Coronavirus, Vaccine Refusal","enrollment":462},{"nctId":"NCT06175494","phase":"PHASE3","title":"A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)","status":"UNKNOWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-12-19","conditions":"COVID-19","enrollment":4800},{"nctId":"NCT05604690","phase":"PHASE1","title":"Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Intravacc B.V.","startDate":"2022-11-03","conditions":"COVID-19","enrollment":40},{"nctId":"NCT05775887","phase":"PHASE1","title":"A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2023-05-08","conditions":"COVID-19","enrollment":70},{"nctId":"NCT04942405","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-06-21","conditions":"Covid19","enrollment":1290},{"nctId":"NCT06282692","phase":"PHASE3","title":"INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-06-19","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":400},{"nctId":"NCT05383560","phase":"PHASE2","title":"Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection","enrollment":179},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04930003","phase":"PHASE1, PHASE2","title":"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2021-06-15","conditions":"Covid19, SARS-CoV Infection, Vaccine Adverse Reaction","enrollment":244},{"nctId":"NCT04873128","phase":"NA","title":"Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2021-06-10","conditions":"Genetic Predisposition","enrollment":110},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":"COVID-19","enrollment":11349},{"nctId":"NCT04993365","phase":"PHASE4","title":"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-05","conditions":"COVID-19","enrollment":520},{"nctId":"NCT04674189","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-12-23","conditions":"Coronavirus, Covid19, SARS-CoV-2","enrollment":2357},{"nctId":"NCT06068569","phase":"PHASE3","title":"Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2023-10","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04551547","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2020-10-31","conditions":"COVID-19","enrollment":552},{"nctId":"NCT06057025","phase":"PHASE3","title":"Study of \"Sputnik Lite\" for the Prevention of COVID-19 With Altered Antigenic Composition.","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2023-09","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04515147","phase":"PHASE2","title":"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-09-21","conditions":"Coronavirus, Covid19, SARS-CoV-2","enrollment":668},{"nctId":"NCT04911790","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-05","conditions":"COVID-19","enrollment":131650},{"nctId":"NCT05198336","phase":"PHASE4","title":"Immunogenicity of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-01-08","conditions":"COVID-19","enrollment":395},{"nctId":"NCT04992208","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-07-24","conditions":"COVID-19","enrollment":31041},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT05007275","phase":"PHASE1","title":"A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-10-10","conditions":"Covid19, SARS-CoV-2 Infection","enrollment":28},{"nctId":"NCT05085613","phase":"NA","title":"Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2021-10-31","conditions":"Beliefs","enrollment":100},{"nctId":"NCT05851911","phase":"","title":"Passive Transmission of COVID-19 Antibody From Mother to Infant","status":"UNKNOWN","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2022-09-01","conditions":"Passive Transmission of Maternal and Infant Antibodies","enrollment":300},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05018078","phase":"NA","title":"Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2021-08-30","conditions":"Patients With Cancers, COVID-19, Vaccine","enrollment":300},{"nctId":"NCT05520970","phase":"PHASE2","title":"Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1","status":"TERMINATED","sponsor":"Cellid Co., Ltd.","startDate":"2022-08-19","conditions":"COVID-19, Vaccines","enrollment":4},{"nctId":"NCT05911087","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2023-06-20","conditions":"Immunogenicity, Safety","enrollment":800},{"nctId":"NCT05124561","phase":"PHASE3","title":"Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)","status":"WITHDRAWN","sponsor":"CanSino Biologics Inc.","startDate":"2021-12-15","conditions":"COVID-19","enrollment":0},{"nctId":"NCT04510207","phase":"PHASE3","title":"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-07-16","conditions":"COVID-19","enrollment":44101},{"nctId":"NCT04526990","phase":"PHASE3","title":"Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-09-15","conditions":"COVID-19","enrollment":44247},{"nctId":"NCT05895110","phase":"NA","title":"To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-29","conditions":"COVID-19","enrollment":240},{"nctId":"NCT05890521","phase":"PHASE4","title":"Safety Study of COVID19 Vaccine on the Market","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-02","conditions":"COVID-19","enrollment":100000},{"nctId":"NCT05197712","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease","status":"UNKNOWN","sponsor":"Baiya Phytopharm Co., Ltd.","startDate":"2022-03-28","conditions":"COVID-19 Vaccine","enrollment":24},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04612972","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-09-09","conditions":"COVID-19","enrollment":12000},{"nctId":"NCT05096845","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-08-25","conditions":"COVID-19 Pandemic","enrollment":22500},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT05580159","phase":"PHASE3","title":"New Generation mRNA Booster Vaccine Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10","conditions":"Immunogenicity, Efficacy, Safety","enrollment":2000},{"nctId":"NCT05614245","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant","status":"WITHDRAWN","sponsor":"VBI Vaccines Inc.","startDate":"2023-03","conditions":"COVID-19, Coronavirus Infections","enrollment":0},{"nctId":"NCT04870593","phase":"NA","title":"What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India","status":"COMPLETED","sponsor":"National Bureau of Economic Research, Inc.","startDate":"2021-04-17","conditions":"Aging, Covid19","enrollment":3006},{"nctId":"NCT05258669","phase":"PHASE2, PHASE3","title":"Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults","status":"UNKNOWN","sponsor":"Ocugen","startDate":"2022-02-20","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05246137","phase":"PHASE3","title":"A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-02-03","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":2646},{"nctId":"NCT05548439","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a","status":"UNKNOWN","sponsor":"VBI Vaccines Inc.","startDate":"2022-10-05","conditions":"COVID-19, Coronavirus Infections","enrollment":103},{"nctId":"NCT05552950","phase":"PHASE4","title":"The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals","status":"UNKNOWN","sponsor":"Chemi-Pharm AS","startDate":"2022-05-01","conditions":"SARS CoV 2 Infection","enrollment":2000},{"nctId":"NCT05407142","phase":"PHASE3","title":"An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-07","conditions":"Coronavirus Infections, Vaccine","enrollment":29000},{"nctId":"NCT04449276","phase":"PHASE1","title":"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-06-18","conditions":"Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2","enrollment":280},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05364047","phase":"PHASE1","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine in China","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2021-07-31","conditions":"COVID-19","enrollment":144},{"nctId":"NCT05447065","phase":"NA","title":"Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.","status":"COMPLETED","sponsor":"Ege University","startDate":"2022-05-07","conditions":"COVID-19 Pandemic, D Vitamin Deficiency, Antibody Hypersensitivity","enrollment":33},{"nctId":"NCT05480436","phase":"PHASE4","title":"Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2022-08-05","conditions":"Hemolysis, COVID-19","enrollment":1200},{"nctId":"NCT05148949","phase":"PHASE4","title":"Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-12-22","conditions":"COVID-19, Pulmonary Tuberculosis","enrollment":240},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04383574","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2020-05-22","conditions":"COVID-19","enrollment":422},{"nctId":"NCT05398926","phase":"PHASE4","title":"Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05107557","phase":"PHASE4","title":"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-11-05","conditions":"COVID-19","enrollment":520},{"nctId":"NCT05165732","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-20","conditions":"COVID-19","enrollment":480},{"nctId":"NCT04798001","phase":"PHASE1","title":"Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults","status":"UNKNOWN","sponsor":"Meissa Vaccines, Inc.","startDate":"2021-04-12","conditions":"Covid19","enrollment":130},{"nctId":"NCT04885907","phase":"PHASE4","title":"Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Vaccine Response Impaired, Immune Suppression, Covid19","enrollment":120},{"nctId":"NCT04530656","phase":"PHASE1","title":"Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2020-08-28","conditions":"COVID-19","enrollment":168},{"nctId":"NCT04860258","phase":"PHASE3","title":"COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities","status":"TERMINATED","sponsor":"CureVac","startDate":"2021-04-22","conditions":"Coronavirus, Covid19, SARS-CoV-2","enrollment":129}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL6068383","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068383"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":43,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 7","pmid":"41621118","title":"COVID-19 vaccine policy: a response and way forward.","journal":"Vaccine"},{"date":"2025 Nov","pmid":"40639387","title":"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.","journal":"The Lancet. Infectious diseases"},{"date":"2025 Feb 1","pmid":"39951082","title":"Sociodemographic Factors Associated With Established and Novel Antenatal Vaccination Uptake in a Cohort of Pregnant Women in Uganda.","journal":"The Pediatric infectious disease journal"},{"date":"2024 Dec 5","pmid":"39772035","title":"Automated, Quantitative Capillary Western Blots to Analyze Host Cell Proteins in COVID-19 Vaccine Produced in Vero Cell Line.","journal":"Vaccines"},{"date":"2025 Jan","pmid":"39581372","title":"Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: A test-negative design.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Investigational COVID-19 Vaccine","companyName":"BioNTech","companyId":"biontech","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":20,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:19.236073+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}